Treatment of Chronic Hepatitis C: Current and Future

Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 369)

Abstract

Resolution of the three-dimensional structures of several Hepatitis C virus (HCV) proteins, together with the development of replicative cell culture systems, has led to the identification of a number of potential targets for direct-acting antiviral agents (DAA). Numerous families of drugs that potently inhibit the HCV life cycle in vitro have been identified, and some of these molecules have reached early to late clinical development. Two NS3-4A protease inhibitors, telaprevir and boceprevir, were approved in Europe and the United States in 2011 in combination with pegylated interferon (IFN)-α and ribavirin for the treatment of chronic hepatitis C related to HCV genotype 1. A number of other DAAs are at the clinical developmental stage in combination with pegylated IFN-α and ribavirin or with other DAAs in IFN-free regimens, with or without ribavirin. They include second-wave, first-generation, and second-generation NS3-4A protease inhibitors, nucleoside/nucleotide analogue inhibitors, and non-nucleoside inhibitors of HCV RNA-dependent RNA polymerase, inhibitors of nonstructural protein 5A and host-targeted agents, such as cyclophilin A inhibitors and microRNA-122 antagonists. The proof of concept that IFN-free regimens can lead to HCV eradication has recently been brought. This chapter provides an overview of the current treatment of HCV infection and discusses the future of HCV therapy with new anti-HCV drugs.

Keywords

Sustained Virological Response Sustained Virological Response Rate Triple Combination Rapid Virological Response NS5A Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflicts of Interest

The author has received grant/research support from Gilead and Roche; he has served as an advisor for Abbott, Achillion, Anadys, Biotica, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, Glaxo-SmithKline, Janssen, Merck, Novartis, Pfizer, and Roche.

References

  1. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F et al (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364:1207–1217PubMedCrossRefGoogle Scholar
  2. Brainard DM, Perty A, van Dyck K, Nachbar RB, de Lepeleire I, Caro L, Stone JA et al (2010) Safety and antiviral activity of MK-5172, a novel HCV NS3/4A protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology 52:706A–707AGoogle Scholar
  3. Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourliere M et al (2006) Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 131:1040–1048PubMedCrossRefGoogle Scholar
  4. Brown NA, Vig P, Ruby E, Muchnik A, Pottorf E, Knox SJ, Febbraro S et al (2010) Safety and pharmacokinetics of PPI-461, a potent new hepatitis C virus NS5A inhibitor with pan-genotype activity. Hepatology 52:S464Google Scholar
  5. Chayama K, Takahashi S, Kawakami Y, Ikeda K, Suzuki F, Toyota J, Karino Y et al (2011) Dual oral combination therapy with the NS5A inhibitor BMS-790052 and the NS3 protease inhibitor BMS-650032 achieved 90% sustained virologic response (SVR12) in HCV genotype 1b-infected null responders. Hepatology 54:1428AGoogle Scholar
  6. Chevaliez S, Rodriguez C, Soulier A, Ahmed-Belkacem A, Hézode C, Pawlotsky JM (2011) Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations. J Hepatol 54(1):S30CrossRefGoogle Scholar
  7. Chevaliez S, Rodriguez C, Pawlotsky JM (2012) New virologic tools for management of chronic hepatitis B and C. Gastroenterology 142:1303–1313PubMedCrossRefGoogle Scholar
  8. Chu TW, Kulkarni R, Gane EJ, Roberts SK, Stedman C, Angus PW, Ritchie B et al (2012) Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology 142:790–795PubMedCrossRefGoogle Scholar
  9. Coelmont L, Kaptein S, Paeshuyse J, Vliegen I, Dumont JM, Vuagniaux G, Neyts J (2008) Debio 025, a cyclophilin binding molecule, is highly efficient in clearing HCV replicon containing cells, alone or when combined with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother 53:967–976PubMedCrossRefGoogle Scholar
  10. Coelmont L, Gallay P, Bobardt M, Kaptein S, Paeshuyse J, Vliegen I, Vuagniaux G et al (2009) Particular in vitro anti-HCV activities and resistance profile of the cyclophylin inhibitor DEBIO-025. J Hepatol 50(1):S36CrossRefGoogle Scholar
  11. Dahari H, Guedj J, Perelson AS, Layden TJ (2011) Hepatitis C viral kinetics in the era of direct acting antiviral agents and IL28B. Curr Hepat Rep 10:214–227PubMedCrossRefGoogle Scholar
  12. de Bruijne J, de Rooij JV, van Vliet A, Leempoels J, Zhou XJ, Weegink C, Molenkamp R et al (2010) Phase I study in healthy volunteers and patients with IDX-375, a novel non-nucleoside HCV polymerase inhibitor. Hepatology 52:1219AGoogle Scholar
  13. Detishin V, Haazen W, Robison H, Robarge L, Olek E (2010) Virological response, safety and pharmacokinetic profile following single- and multiple-dose administration of ACH-0141625 protease inhibitor to healthy volunteers and HCV genotype 1 patients. J Hepatol 52(1):S468CrossRefGoogle Scholar
  14. Erhardt A, Deterding K, Benhamou Y, Reiser M, Forns X, Pol S, Calleja JL et al (2009) Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antiviral Ther 14:23–32Google Scholar
  15. European Association for the Study of the Liver (2011) EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 55:245–264Google Scholar
  16. Forestier N, Larrey D, Guyader D, Marcellin P, Rouzier R, Patat A, Smith P et al (2011) Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. J Hepatol 54:1130–1136PubMedCrossRefGoogle Scholar
  17. Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M (2011) Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol 85:7312–7320PubMedCrossRefGoogle Scholar
  18. Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, Ipe D et al (2010) Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376:1467–1475PubMedCrossRefGoogle Scholar
  19. Gane EJ, Stedman CA, Hyland RH, Sorensen RD, Symonds WT, Hindes R, Berrey MM (2011) Once daily PSI-7977 plus RBV: pegylated interferon alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3. Hepatology 54(1):377ACrossRefGoogle Scholar
  20. Gane EJ, Stedman CA, Hyland RH, Sorensen RD, Symonds WT, Hindes RG, Berrey MM (2012) ELECTRON: once daily PSI-7977 plus RBV in HCV GT1/2/3. J Hepatol 56(2):S438CrossRefGoogle Scholar
  21. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH et al (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96–100PubMedCrossRefGoogle Scholar
  22. Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335–1374PubMedCrossRefGoogle Scholar
  23. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American association for the study of liver diseases. Hepatology 54:1433–1444PubMedCrossRefGoogle Scholar
  24. Goldwater R, DeMicco M, Zong JA, Chittik GE, Yuen GJ, West S, Kagel J et al (2010) Safety, pharmacokinetics and antiviral activity of single oral doses of the HCV NS3 protease inhibitor GS-9256. Hepatology 52:717A–718AGoogle Scholar
  25. Guedj J, Perelson AS (2011) Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology 53:1801–1808PubMedCrossRefGoogle Scholar
  26. Herrmann E, Lee HJ, Marinos G, Modi M, Zeuzem S (2003) Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 37:1351–1358PubMedCrossRefGoogle Scholar
  27. Hotho D, deBruijne J, O’Farrell A, Boyea T, Li J, Weegink CJ, Schinkel J et al (2009) Accelerated clinical trial design to assess the safety, tolerability and antiviral activity of PHX1766, a novel HCV NS3/4A protease inhibitor in healthy volunteers and chronic hepatitis C patients. Hepatology 50:1031A–1032AGoogle Scholar
  28. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P et al (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364:2405–2416PubMedCrossRefGoogle Scholar
  29. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, Kwong AD et al (2007) Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46:631–639PubMedCrossRefGoogle Scholar
  30. Larrey D, Benhamou Y, Lohse AW, Trepo C, Moelleken C, Bronowicki JP, Arasteh K et al (2009) Safety, pharmacokinetics and antiviral effect of BI207127, a novel HCV RNA polymerase inhibitor, after 5 days oral treatment in patients with chronic hepatitis C. J Hepatol 50(1):S383–S384CrossRefGoogle Scholar
  31. Lawitz E, Sulkowski M, Jacobson I, Faruqui S, Kraft WK, Maliakkal B, Allbrahim M et al (2008) Safety, tolerability and antiviral activity of MK-7009, a novel inhibitor of the hepatitis C virus NS3/4A protease, in patients with chronic HCV genotype 1 infection. Hepatology 48:403AGoogle Scholar
  32. Lawitz E, Rodriguez-Torres M, DeMicco M, Nguyen T, Godofsky E, Appleman J, Rahimy M et al (2009) Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients. J Hepatol 50(1):S384CrossRefGoogle Scholar
  33. Lawitz E, Gaultier I, Poordad F, De Jesus E, Kowdley K, Sepulveda G, Cohen D et al (2010) Four week virologic response and safety of ABT-450 given with low-dose ritonavir (ABT-450r) in combination with pegylated interferon alfa-2a and ribavirin after 3-day monotherapy in genotype 1 HCV-infected treatment-naive subjects. Hepatology 52:878A–879AGoogle Scholar
  34. Lawitz E, Hill JM, Marbury TC, Rodriguez-Torres M, DeMicco M, Quesada J, Shaw P et al (2010) Three-day, dose-ranging study of the HCV NS3 protease inhibitor GS-9451. Hepatology 52:714A–715AGoogle Scholar
  35. Lawitz E, Rodriguez-Torres M, Denning J, Cornpropst M, Clemons D, McNair L, Berrey M et al (2011) Once daily dual nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA < LOD at day 14: first purine/pyrimidin clinical combination data (the NUCLEAR study). J Hepatol 54:S543Google Scholar
  36. Lawitz E, Gruener D, Hill J, Marbury T, Komjathy S, DeMicco M, Murillo A et al (2011b) Three-day dose ranging study of the HCV NS5A inhibitor GS-5885. J Hepatol 54(1):S481–S482CrossRefGoogle Scholar
  37. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R et al (2012) Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 366:216–224PubMedCrossRefGoogle Scholar
  38. Manns MP, Reesink H, Moreno C, Berg T, Benhamou Y, Horsmans Y, Dusheiko G et al (2008) Safety and antiviral activity of TMC435350 in treatment-naive genotype 1 HCV-infected patients. Hepatology 48:1023ACrossRefGoogle Scholar
  39. Manns MP, Bourliere M, Benhamou Y, Pol S, Bonacini M, Trepo C, Wright D et al (2011) Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 54:1114–1122PubMedCrossRefGoogle Scholar
  40. Nettles R, Chien C, Chung E, Persson A, Gao M, Belema M, Meanwell NA et al (2008) BMS-790052 is a first-in-class potent hepatitis C virus NS5A inhibitor for patients with chronic HCV infection: results from a proof-of-concept study. Hepatology 48:1025AGoogle Scholar
  41. Nettles R, Wang XD, Quadri S, Wu YS, Gao M, Belema M, Lawitz E et al (2010) BMS-824393 is a potent HCV NS5A inhibitor with substantial antiviral activity when given as monotherapy in subjects with chronic genotype 1 HCV infection. Hepatology 52:1203A–1204AGoogle Scholar
  42. Pawlotsky JM (2011) Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 53:1742–1751PubMedCrossRefGoogle Scholar
  43. Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, Castera L et al (2004) Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 126:703–714PubMedCrossRefGoogle Scholar
  44. Picard O, Cacoub P (2012) Dermatological adverse effects during genotype-1 hepatitis C treatment with the protease inhibitors telaprevir and boceprevir. Patient management. Clin Res Hepatol Gastroenterol 36:437–440Google Scholar
  45. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM et al (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195–1206PubMedCrossRefGoogle Scholar
  46. Poordad FF, Lawitz EJ, Reddy KR, Afdhal NH, Hezode C, Zeuzem S, Lee SS et al (2012) A randomized trial comparing ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin. J Hepatol 56(2):S559CrossRefGoogle Scholar
  47. Powdrill MH, Tchesnokov EP, Kozak RA, Russell RS, Martin R, Svarovskaia ES, Mo H et al (2011) Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci USA 108:20509–20513PubMedCrossRefGoogle Scholar
  48. Reddy R, Rodriguez-Torres M, Gane EJ, Robson R, Lalezari J, Everson GT, DeJesus E et al (2007) Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology 46:862A–863AGoogle Scholar
  49. Reesink H, Bergmann J, de Bruijne J, Weegink C, van Lier J, van Vliet A, Keung A et al (2009) Safety and antiviral activity of SCH 900518 administered as monotherapy and in combination with peginterferon alfa-2b to naive and treatment-experienced HCV-1 infected patients. J Hepatol 50(1):S35CrossRefGoogle Scholar
  50. Reesink HW, Janssen HLA, Zeuzem S, Lawitz EJ, Rodriguez-Torres M, Patel K, Chen A et al (2012) Final results. Randomized, double-blind, placebo-controlled safety, antiviral proof-of-concept study of miravirsen, an oligonucleotide targeting miR-122, in treatment-naive patients with genotype 1 chronic HCV infection. J Hepatol 56(2):S26CrossRefGoogle Scholar
  51. Rodriguez-Torres M, Lawitz E, Conway B, Kaita K, Sheikh A, Ghalib R, Adrover R et al (2010) Safety and antiviral activity of the HCV non-nucleoside polymerase inhibitor VX-222 in treatment-naive genotype 1 HCV infected patients. J Hepatol 52(1):S14CrossRefGoogle Scholar
  52. Rouzier R, Larrey D, Gane EJ, Wiercinska-Drapalo A, Chang L, Zhang Y, Gujral B et al (2011) Activity of danoprevir plus low-dose ritonavir in combination with peginterferon alfa-2a plus ribavirin in previous null-responders. J Hepatol 54(1):S28CrossRefGoogle Scholar
  53. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, Wincheringer D et al (2007) Dynamic HCV genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir (VX-950). Gastroenterology 132:1767–1777PubMedCrossRefGoogle Scholar
  54. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW et al (2011) Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365:1014–1024PubMedCrossRefGoogle Scholar
  55. Suzuki F, Ikeda K, Toyota J, Karino Y, Ohmura T, Chayama K, Takahashi S et al (2012) Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or ineligible/intolerant to peginterferon/ribavirin. J Hepatol 56(2):S7CrossRefGoogle Scholar
  56. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A et al (2010) A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 139:1593–1601PubMedCrossRefGoogle Scholar
  57. Targett-Adams P, Graham EJ, Middleton J, Palmer A, Shaw SM, Lavender H, Brain P et al (2011) Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. J Virol 85:6353–6368PubMedCrossRefGoogle Scholar
  58. Thomas E, Ghany MG, Liang TJ (2012) The application and mechanism of action of ribavirin in therapy of hepatitis C. Antivir Chem Chemother 23:1–12PubMedCrossRefGoogle Scholar
  59. Wagner F, Thompson R, Kantaridis C, Simpson P, Troke PJ, Jagannatha S, Neelakantan S et al (2011) Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology 54:50–59PubMedCrossRefGoogle Scholar
  60. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R et al (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364:2417–2428PubMedCrossRefGoogle Scholar
  61. Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C et al (2012) The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 55:749–758PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.National Reference Center for Viral Hepatitis B, C and Delta, Department of Virology, Hôpital Henri MondorUniversité Paris-EstCréteilFrance
  2. 2.INSERM U955CréteilFrance
  3. 3.Department of VirologyHôpital Henri MondorCréteilFrance

Personalised recommendations